Trump drug pricing plan promised broad savings but delivered limited benefits
The Trump administration's "TrumpRx" initiative, originally intended to offer a wide range of cheaper drugs like a supermarket, has instead resulted in a limited, boutique-style program. Critics argue it fails to deliver the widespread affordability originally promised. This gap highlights challenges in implementing meaningful drug pricing reforms.